Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- DNA (5)
- Research (5)
- Development (2)
- Federal funding (2)
- Health law (2)
-
- IP (2)
- Patents (2)
- Privacy (2)
- R & D (2)
- Technology transfer (2)
- Access (1)
- Biotech (1)
- Carcinogens (1)
- Cloning (1)
- Confidentiality (1)
- Control (1)
- Copyright (1)
- Employee (1)
- Employer (1)
- Employers (1)
- Employment (1)
- Ethics (1)
- Gene patents (1)
- Gene sequencing (1)
- Genes (1)
- Genetic data (1)
- Genetic engineering (1)
- Genetic testing (1)
- Genome (1)
- Genomics (1)
- Publication
- Publication Type
Articles 1 - 13 of 13
Full-Text Articles in Genetic Structures
Silencing Innovation: The Patent Eligibility Of Sirna Therapeutics, Alexander M. Walker
Silencing Innovation: The Patent Eligibility Of Sirna Therapeutics, Alexander M. Walker
Minnesota Journal of Law, Science & Technology
No abstract provided.
A Myriad Of Reasons: Incentives For Innovation In Genetic Research And Diagnostics Post-Myriad, Zachary King
A Myriad Of Reasons: Incentives For Innovation In Genetic Research And Diagnostics Post-Myriad, Zachary King
North Carolina Central University Science & Intellectual Property Law Review
No abstract provided.
Genomics Unbound: The Scientific And Legal Case Against Patents Based On Naturally Occurring Dna Sequences, Fazal Khan
Genomics Unbound: The Scientific And Legal Case Against Patents Based On Naturally Occurring Dna Sequences, Fazal Khan
Scholarly Works
While there have been mixed opinions as to whether gene patents were dead in light of Prometheus,this Article argues that a proper understanding of patent law, genomics, and public policy concerns should lead to no other result. The primary focus of this piece is to rebut certain vested interests in the biotechnology industry and affirm the normative claim that gene patents improperly fetter genomics research and development. First, through the lens of the Myriad case, we will recount why there was such a strong public interest movement against recognizing such patents. Specifically, we will show how patents on naturally occurring …
Gene Patents No More? Deciphering The Meaning Of Prometheus, Fazal Khan, Lindsay Kessler
Gene Patents No More? Deciphering The Meaning Of Prometheus, Fazal Khan, Lindsay Kessler
Scholarly Works
When Congress enacted the United States Patent Act in 1952, it specified that patentable subject matter included anything “under the sun that is made by man.” Three decades ago the United States Patent and Trademark Office (USPTO) issued the first gene patent and ushered in a brave new gold rush. Some genes are associated with specific diseases, so being able to identify these sequences is an essential first step for developing genomic diagnostic tests and therapies. The problem with gene patents is that they allow modern-day prospectors to cordon off access to naturally occurring DNA sequences and exclude others from …
Genetic Monitoring In The Workplace: A Tool Not A Solution, Lillian Trettin, Catherine Musham, Richard Jablonski
Genetic Monitoring In The Workplace: A Tool Not A Solution, Lillian Trettin, Catherine Musham, Richard Jablonski
RISK: Health, Safety & Environment (1990-2002)
The authors differentiate between genetic monitoring and screening, and discuss the potential risks and benefits of predictive testing technologies.
Harnessing The Human Genome Through Legislative Restraint, George P. Smith Ii
Harnessing The Human Genome Through Legislative Restraint, George P. Smith Ii
Scholarly Articles
The awesome predictive power of genetic medicine promises great advancements in not only the treatment of identifiable conditions but the prevention of their pathological manifestations. At the same time, the release and dissemination of this genetic or medical information poses a distinct risk of loss of privacy and stigmatization to carriers of genetic disorders. In order to safeguard the individual right of autonomy, privacy, confidentiality and informed consent-yet accommodate the legitimate interests of employers and insurers to obtain medical information relevant to their professional needs and economic responsibilities a balance must be struck legislatively at the federal and state levels …
Social Issues Of Genome Innovation And Intellectual Property, Elaine Alma Draper
Social Issues Of Genome Innovation And Intellectual Property, Elaine Alma Draper
RISK: Health, Safety & Environment (1990-2002)
Dr. Draper's focus is the use of personal information derived from genome research. She identifies several potential problems, including access to and control of genetic information, employment discrimination and social stratification. She also recommends possible solutions.
Review Of: The Genetic Frontier: Ethics, Law, And Policy (Mark S. Frankel & Albert Teich Eds., American Association For The Advancement Of Science 1994), Suzanne A. Sprunger
Review Of: The Genetic Frontier: Ethics, Law, And Policy (Mark S. Frankel & Albert Teich Eds., American Association For The Advancement Of Science 1994), Suzanne A. Sprunger
RISK: Health, Safety & Environment (1990-2002)
Review of: The Genetic Frontier: Ethics, Law, and Policy (Mark S. Frankel & Albert Teich eds., American Association for the Advancement of Science 1994). Acknowledgments, appendix, contributors, figures, index, introduction, notes, references, tables. LC 93-37230, ISBN 0-87168-526-4. [260 pp. Paper $22.95. 1333 H St., NW, Washington DC 20005.]
Maximizing The Return From Genome Research: Introduction, Thomas G. Field Jr.
Maximizing The Return From Genome Research: Introduction, Thomas G. Field Jr.
RISK: Health, Safety & Environment (1990-2002)
Professor Field introduces and explains the origins of the symposium.
Overview Of Federal Technology Transfer, Lawrence Rudolph
Overview Of Federal Technology Transfer, Lawrence Rudolph
RISK: Health, Safety & Environment (1990-2002)
Mr. Rudolph reviews approximately thirteen years of legal and political developments that have contributed to laws governing the extent to which private firms may secure rights in technology at least partly developed with federal funds.
Technology Transfer: A View From The Trenches, Harvey Drucker
Technology Transfer: A View From The Trenches, Harvey Drucker
RISK: Health, Safety & Environment (1990-2002)
Dr. Drucker, who has lab-wide responsibility for technology transfer at Argonne National Laboratory, argues that transferring rights in discoveries made through tax supported research to private entities can contribute to public welfare in many ways.
Origins Of The Human Genome Project, Robert Mullan Cook-Deegan
Origins Of The Human Genome Project, Robert Mullan Cook-Deegan
RISK: Health, Safety & Environment (1990-2002)
Dr. Cook-Deegan recounts some of the scientific and political history leading to controversy about the proper mix of private and public roles in pursuing genome research and bringing its fruits to bear, e.g., in preventing and curing disease.
Overview Of Potential Intellectual Property Protection For Biotechnology, Kate H. Murashige
Overview Of Potential Intellectual Property Protection For Biotechnology, Kate H. Murashige
RISK: Health, Safety & Environment (1990-2002)
Dr. Murashige compares the function and value of copyright, patent and trade secret laws in recovering investments in developing genome-related biotechnology.